Analyst Ratings For NuVasive, Inc. (NASDAQ:NUVA)
Today, Royal Bank of Canada raised its price target on NuVasive, Inc. (NASDAQ:NUVA) to $70.00 per share.
There are 8 Buy Ratings, 7 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on NuVasive, Inc. (NASDAQ:NUVA) is Hold with a consensus target price of $68.5333 per share, a potential 11.13% upside.
Some recent analyst ratings include
- 10/31/2018-NuVasive, Inc. (NASDAQ:NUVA) had its Buy ➝ Buy rating reiterated by Needham & Company LLC with a $75.00 price target
- 10/19/2018-NuVasive, Inc. (NASDAQ:NUVA) had its Hold rating reiterated by Cantor Fitzgerald with a $58.00 price target
- 9/27/2018-NuVasive, Inc. (NASDAQ:NUVA) gets upgraded to Outperform by Robert W. Baird with a price target of $82.00
- On 11/21/2018 Matthew Link, Insider, sold 4,889 with an average share price of $62.22 per share and the total transaction amounting to $304,193.58.
- On 11/19/2018 Matthew Link, Insider, sold 2,582 with an average share price of $62.02 per share and the total transaction amounting to $160,135.64.
- On 11/16/2018 Matthew Link, Insider, sold 1,200 with an average share price of $62.01 per share and the total transaction amounting to $74,412.00.
- On 3/6/2018 Gregory T Lucier, CEO, bought 6,000 with an average share price of $50.30 per share and the total transaction amounting to $301,800.00.
- On 3/1/2018 Gregory T Lucier, CEO, bought 6,000 with an average share price of $48.57 per share and the total transaction amounting to $291,420.00.
- On 8/29/2017 Gregory T Lucier, CEO, bought 2,000 with an average share price of $61.52 per share and the total transaction amounting to $123,040.00.
- On 8/18/2017 Lesley H. Howe, Director, sold 3,970 with an average share price of $64.64 per share and the total transaction amounting to $256,620.80.
About NuVasive, Inc. (NASDAQ:NUVA)
NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine and to perform restorative and fusion procedures in a minimally-disruptive fashion. Its biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty, which are used for spinal fusion or bone healing process. The company's IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. It also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, the company offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. NuVasive, Inc. sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.
Recent Trading Activity for NuVasive, Inc. (NASDAQ:NUVA)
Shares of NuVasive, Inc. closed the previous trading session at 61,44 −0,78 1,25 % with 62.17 shares trading hands.
